Skip to main content

Table 1 Patient demographics and disease characteristics (efficacy population)

From: Efficacy and safety of moxifloxacin in community acquired pneumonia: a prospective, multicenter, observational study (CAPRIVI)

Parameter

Total N = 2152 (100%)

Gender, n (%)

 

  Male

1220 (56.7)

  Female

918 (42.7)

  Missing

14 (0.7)

Mean (SD) age, y (n = 2136)

53.3 (17.9)

Mean (SD) weight, kg (n = 2117)

77.3 (15.0)

Mean (SD) height, cm (n = 2099)

170.9 (9.0)

Mean (SD) BMI, kg/m2 (n = 2098)

26.5 (4.8)

Race, n (%)

 

  White

1833 (85.2)

  Asian

119 (5.5)

  Black

3 (0.1)

  Other

4 (0.2)

  Missing

193 (9.0)

Smoking status, n (%)

 

  Non-smoker

1331 (61.8)

  Present smoker

501 (23.3)

  Past smoker

276 (12.8)

  Missing

44 (2.0)

Type of vaccination, n (%)

 

  None

1546 (71.8)

  Pneumococcus

8 (0.4)

  Influenza

237 (11.0)

  Both

18 (0.8)

  Missing

343 (15.9)

Pneumonia episodes in past 12 months

 

  Yes

187 (8.7)

  No

1838 (85.4)

  Unknown

81 (3.8)

  Missing

46 (2.1)

Hospitalization in past 12 months

 

  Yes

319 (14.8)

    Due to CAP

112 (35.1)

    Other

178 (55.8)

    Missing

40 (12.5)

  No

1740 (80.9)

    Unknown

53 (2.5)

    Missing

40 (1.9)